@DrAtulJG Profile picture

Dr. Atul Jayaprakash

@DrAtulJG

Indian | Malayali | Doctor | Medical Oncologist | Investor | Opinionist | Random Thoughts |

Joined August 2020
Similar User
Neelima Ventrapragada photo

@drneelima_onco

Abey Sushan photo

@AbeySushan

Jayan C photo

@c_jayan

Vishwajeeth K Pai photo

@paivishwajeeth

Dr. Atul Jayaprakash Reposted

⭐️Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (KEYNOTE-522) nej.md/3XzBOIS Editorial: Immunotherapy for Early-Stage Triple-Negative Breast Cancer nej.md/3On5K5y


Dr. Atul Jayaprakash Reposted

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: nej.md/4eGp1tj

Tweet Image 1

Dr. Atul Jayaprakash Reposted

Good day to remind a good old ADC Easter egg - first trop2 ADC for TNBC = IMMU132 (saci gov) - second trop2 ADC for TNBC = SKB264 (saci tmt)

Sacituzumab tirumotecan (aka sac-TMT aka SKB264) approved in China for patients with advanced or metastatic triple negative breast cancer (TNBC) who have received at least 2 prior therapies. This brings the total number of approved ADCs to 13 worldwide (of which 11 by US FDA)!

Tweet Image 1


What a misleading tweet! Apparently there was no contribution to cancer remission from immunotherapy, chemotherapy, or radiotherapy! 🤷‍♂️

Navjot S Sidhu's was diagnosed with Stage-IV cancer. Doctors claimed just a 3% chance of survival! ~ She took lemon water, raw turmeric, apple cider vinegar, Neem leaves, & Tulsi in the diet. This diet made her Cancer FREE in just 40 days🤯👌🏼



Dr. Atul Jayaprakash Reposted

Updated @ASCO guidelines in small-cell carcinoma lung. Treatment landscape in SCLC is changing rapidly. Long overdue! ascopubs.org/doi/10.1200/JC…

Tweet Image 1
Tweet Image 2

Dr. Atul Jayaprakash Reposted

USPSTF Recommendations for Breast Cancer Screening 🟣Women 40–74: Biennial mammography recommended 🟣Women 75+: Evidence insufficient for benefit vs. harm. 🟣Dense breasts: Insufficient evidence for additional imaging (e.g., ultrasound/MRI). #BreastCancerAwareness @JAMA_current

Tweet Image 1

Dr. Atul Jayaprakash Reposted

The Government of India, in association with the Ministry of Ayush is going to start "super specialist" Doctorate in Hepatology training for Ayurveda practitioners without realising what Ayurveda can really do to the liver.

Tweet Image 1

Dr. Atul Jayaprakash Reposted

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer NIAGARA trial EFS and OS ✅️ nejm.org/doi/full/10.10…

Tweet Image 1

Dr. Atul Jayaprakash Reposted

One of the greatest lies in India is that The Government spends crores on the education of a Postgraduate Resident. Nothing cd be farther from the truth. Actually, the converse is true. No medical college hospital in TN or elsewhere, can function to even 50% of…


Dr. Atul Jayaprakash Reposted

VERY IMPORTANT: 😡😡😡😡😡😡😡😡😡 *Doctors and paramedical attention please!!! A medical oncologist at Kalaignar Centenary Superspeciality hospital, Guindy was brutally stabbed at neck today Nov 13 at 10.30am. His condition is very critical. Pray for him, please!


Dr. Atul Jayaprakash Reposted

🧮First-line chemotherapies in advanced pancreatic cancer @TheLancetOncol ✅Meta-analysis reaffirms NALIRIFOX /FOLFIRINOX as first-line regimens @TheLancet @OncoAlert @realbowtiedoc #cancer #oncology #MedX

Tweet Image 1
Tweet Image 2
Tweet Image 3

Dr. Atul Jayaprakash Reposted

It's concerning to see a major newspaper like @timesofindia promoting pseudoscience. Their reach can mislead many, especially in a country where Ayurveda is considered 'natural' and free of side effects! It's a harmful misconception 😭 #MedTwitter

Tweet Image 1

Dr. Atul Jayaprakash Reposted

A thread for all confused whether to opt for Radiology or not in #NEETPG2024Counselling? These are my personal insights and opinions WILL vary! There are ENOUGH takers for Radiology Residency seats in India. Unlike in the USA, they will NEVER go vacant in India. But what…


Dr. Atul Jayaprakash Reposted

💉Nivolumab-ipilimumab vs SOC for non-clear cell RCC SUNNIFORECAST trial #EMUC24 ✅Met primary end point 12-month OS rate: 86.9% vs 76.8 @OncoAlert #cancer #oncology #MedX

Tweet Image 1
Tweet Image 2
Tweet Image 3

Dr. Atul Jayaprakash Reposted

Nivolumab Plus Ipilimumab in Aggressive Thyroid Carcinoma ascopost.com/news/november-… #thycsm #thyroidcancer #oncology #immunotherapy


I’m pretty certain that @Cristiano doesn’t start his day with #Herbalife Definitely not #HealthyBreakfast

A good way to start the day? A healthy breakfast. Herbalife Formula 1 delivers a balanced mix of protein, fiber, vitamins, and minerals. #Herbalife #HealthyBreakfast

Tweet Image 1
Tweet Image 2


Dr. Atul Jayaprakash Reposted

🫁 #EGFR classical mutations & concomitant drivers 🫁 📌 #KRAS 📌 #ERRB2 📌 #MET 📌 #BRAF #LungCancer #efgr #LCSM @JCOPO_ASCO

Tweet Image 1

🫁 #EGFR classical mutated #NSCLC 🫁 🫁 Frequency #Concomitant driver alterations 🫁 🌟 Using targeted NGS analysis 🌟 #EGFR #NSCLC #lungcancer #LungCancerAwarenessMonth #LCSM

Tweet Image 1


Dr. Atul Jayaprakash Reposted

📝Dosing of selected anticancer agents in hepatic dysfunction 👇 @ASCO @OncoAlert #cancer #oncology #MedX

Tweet Image 1

Dr. Atul Jayaprakash Reposted

The SERENA-2 ph2 trial of camizestrant vs fulvestrant is out in @TheLancetOncol Cami doubled PFS in ET-pretreated MBC, with most benefit in pts with ESR1 mutations. SERENA-4 and -6 phase 3 trials ongoing. Great editorial by Kristina Fannucci & @elmayermd thelancet.com/journals/lanon…

Tweet Image 1

Dr. Atul Jayaprakash Reposted

📢 ASCIMINIB is now approved for newly diagnosed CML 🙌🏼 Certainly not practice altering, but a good choice to have 👍🏼 #MedTwitter fda.gov/drugs/resource…

Tweet Image 1

United States Trends
Loading...

Something went wrong.


Something went wrong.